Status: Recruiting Patients
A Phase 1b trial entitled MITCI (Melanoma Intra-Tumoral Cavatak and Ipilimumab) to investigate the use of CAVATAK® in combination with Ipilimumab (Yervoy®) in patients with advanced melanoma is underway at Providence Cancer Centre in Portland, Oregon; Oncology Specialists Institute in Chicago, Illinois and John Wayne Cancer Institute in Santa Monica, California.
The trial is designed to evaluate the safety and tolerability of the established dose of intratumoural CAVATAK in combination with Yervoy® in 26 patients with late-stage melanoma for whom Yervoy® would be considered the standard of care.
Investigators will also assess evidence of anti-cancer activity, including response rates and bio-markers of anti-tumour immunity.
For further information about this trial, please visit the Clinical Trial website at: ClinicalTrials.gov Identifier: NCT02307149
Principal Investigator Dr Brendan Curti presented the April 2017 MITCI trial results on an Investor Conference call following the AACR Annual Meeting. Audio available here.